Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...

Oxtellar XR (oxcarbazepine) can cause side effects that range from mild to serious. More common side effects include dizziness and extreme sleepiness. If side effects from Oxtellar XR become ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830 ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

Investors might want to bet on Supernus Pharmaceuticals (SUPN), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine ...

Feb 4 (Reuters) - The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' (SUPN.O), opens new tab drug-device combination to treat movement-related symptoms of Parkinson's ...